Flat Profits At Hafslund Nycomed
Norwegian company Hafslund Nycomed's financial results for the first quarter of 1996 have disappointed, leading Goldman Sachs analysts to downgrade their forecasts for the firm's earnings per share through to 1998.
Pretax profits in the first quarter of 1996 at HN were flat at 456 million Norwegian kroner ($70.3 million). It is understood that some analysts had expected pretax profits to come in at around 500 million kroner. EPS were 3.02 kroner, down from 3.07 kroner in first-quarter 1995.
Before R&D costs, operating profits were 676 million kroner, down 12.7%. R&D costs for the quarter were 206 million kroner, falling from 235 million kroner a year earlier. Revenues were 3% lower than a year ago at 2.36 billion kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze